Watch this talk by Dr. Brynn Levy to hear how Bionano’s Saphyr Genome imaging technology accurately detected all known clinical variants identified by traditional cytogenetic methods.
At Cancer Genomics Consortium (CGC) 2019 annual meeting, Professor Brynn Levy, Director of Cytogenetics at Columbia University, presented a preliminary read-out of 11 leukemia patient samples as part of a multi-center clinical validation study. This study compares Bionano Saphyr to technologies used in traditional cytogenetics methods like karyotype, Fluorescent In-Situ Hybridization (FISH), and Chromosomal MicroArray (CMA). This effort is being run by a consortium of leading cytogenetics teams at institutions in the United States, including Columbia University, the MD Anderson Cancer Center of the University of Texas, the Mayo Clinic, the University of Washington, Penn State University, Augusta University and the PathGroup.
Other CGC presentations included an introduction on Bionano’s genome mapping technology and its use in cancer discovery by Dr. Sven Bocklandt, and a talk by Rashmi Kanagal-Shamanna on her use of Bionano on patients with myelodysplastic syndrome.